Nectin-4 as a Predictive Marker for Poor Prognosis of Endometrial Cancer with Mismatch Repair Impairment

The adhesion molecule Nectin-4 is a new potential therapeutic target for different types of cancer; however, little is known about its diagnosis significance in endometrial cancer (EC). We found that Nectin-4 expression was significantly higher in EC tissues than in nonadjacent normal tissue. The ar...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 15; no. 10; p. 2865
Main Authors Chang, Ha Kyun, Park, Young Hoon, Choi, Jung-A, Kim, Jeong Won, Kim, Jisup, Kim, Hyo Sun, Lee, Hae Nam, Cho, Hanbyoul, Chung, Joon-Yong, Kim, Jae-Hoon
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 22.05.2023
MDPI
Subjects
Analysis
Antibodies
Antigens
Bioinformatics
Biomarkers
Cancer
Cancer patients
Clinical significance
Development and progression
Diagnosis
DNA repair
Endometrial cancer
Endometrium
Genomics
Kinases
Medical prognosis
Metastasis
Mismatch repair
MSH2 protein
Nectin
Oncology, Experimental
Prognosis
Protein deficiency
Statistical analysis
Survival
Survival analysis
Therapeutic applications
Therapeutic targets
United States > US
MSH6
Nectin-4
endometrial cancer
MSH2
Online AccessGet full text

Cover

More Information
Summary:The adhesion molecule Nectin-4 is a new potential therapeutic target for different types of cancer; however, little is known about its diagnosis significance in endometrial cancer (EC). We found that Nectin-4 expression was significantly higher in EC tissues than in nonadjacent normal tissue. The area under the receiver operating characteristic curve value of 0.922 indicated good diagnostic accuracy for Nectin-4 expression in EC. Furthermore, Nectin-4 expression was associated with DNA mismatch repair (MMR) protein deficiency. Notably, the high Nectin-4 expression group of patients with MSH2/6-deficient EC had shorter progression-free survival than that of the low Nectin-4 expression group. The number of lymphovascular space invasion-positive patients in groups with MMR deficiency and high Nectin-4 expression was also increased compared with that in the low Nectin-4 expression group. Bioinformatics analysis revealed that alteration in Nectin-4 and MMR genes is associated with Nectin-4 expression in EC. To the best of our knowledge, this is the first study to show that Nectin-4 expression may be a potential biomarker for EC diagnosis and that high Nectin-4 expression in MMR-deficient patients with EC can predict short progression-free survival, thus providing clues to identify patients for adjuvant therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work and are the first coauthors of this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15102865